Nanocan is currently developing new products to treat pancreatic cancer, cervical cancer, lung cancer, and COVID-19. Preclinical research is also ongoing on the use of the Company's therapeutics to treat breast cancer, prostate cancer, liver cancer, and glioblastoma. Nanocan has a robust research and development program and its drug-development pipeline shows the Company's progress in the table below.

Copyright © 2021 Nanocan Therapeutics Corporation - All Rights Reserved.